Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy

NCT01789827 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Stage IV Skin Melanoma

Interventions

OTHER: Laboratory Biomarker Analysis
PROCEDURE: Radionuclide Imaging
BIOLOGICAL: Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2

Sponsor

Mayo Clinic

Collaborators

[object Object]